Copyright
©The Author(s) 2020.
World J Hepatol. Sep 27, 2020; 12(9): 628-640
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.628
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.628
Table 3 mean (± SD) alanine aminotransferase levels in patients who had direct-acting antiviral therapy responses and failure (baseline, week 4, week 8, and week 12)
| SVR12 Achievement | Baseline ALT, | ALT at treatment week 4, mean (± SD) | ALT at treatment week 8, mean (± SD) | ALT at treatment week 12, mean (± SD) |
| Responders | 80.67 (± 102.447) | 25.21 (± 20.416) | 19.78 (± 11.651) | 20.21 (± 10.994) |
| Failures | 133.00 (±103.057) | 61.17 (± 71.337) | 54.50 (± 63.385) | 56.83 (± 43.938) |
| P values | 0.2 | 0.001 | 0.0001 | 0.0001 |
- Citation: Ismail MS, Hassan M, Khaderi SA, Yousry WA, Kamal El-Din MM, Bahaa El-Din MM, El Sayed OA, Kaseb AO, Goss JA, Kanwal F, Jalal PK. Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World J Hepatol 2020; 12(9): 628-640
- URL: https://www.wjgnet.com/1948-5182/full/v12/i9/628.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i9.628